The Heparin-binding Exosite of Factor IXa is a Critical Regulator of Plasma Thrombin Generation and Venous Thrombosis

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Jul 24

PMID 18647957

Citations 37

Authors

Yang Buyue

Herbert C Whinna

John P Sheehan

Affiliations

Soon will be listed here.

Abstract

The role of the factor IXa heparin-binding exosite in coagulation was assessed with mutations that enhance (R170A) or reduce (R233A) stability of the protease-factor VIIIa A2 domain interaction. After tissue factor (TF) addition to reconstituted factor IX-deficient plasma, factor IX R170A supported a 2-fold increase in velocity index (slope) and peak thrombin concentration, whereas factor IX R233A had a 4- to 10-fold reduction relative to factor IX wild-type. In the absence of TF, 5 to 100 pM of factor IXa increased thrombin generation to approach TF-stimulated thrombin generation at 100% factor IX. Factor IXa R170A demonstrated a 2- to 3-fold increase in peak thrombin concentration and 5-fold increase in velocity index, whereas the response for factor IXa R233A was blunted and delayed relative to wild-type protease. In hemophilia B mice, factor IX replacement reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after FeCl(3)-induced saphenous vein injury. At 5% factor IX, the times to occlusion for factor IX wild-type, R170A, and R233A were 15.7 minutes, 9.1 minutes (P </= .003), and more than 45 minutes. These data support the role of the factor IXa heparin-binding exosite as a critical regulator of coagulation and novel antithrombotic target.

Citing Articles

Protein S antibody as an adjunct therapy for hemophilia B.

Wilson H, Pierre A, Paysse A, Kumar N, Cooley B, Rudra P Blood Adv. 2023; 8(2):441-452.

PMID: 37773781 PMC: 10827407. DOI: 10.1182/bloodadvances.2023010819.

Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo.

Ivanciu L, Arruda V, Camire R Blood. 2023; 141(16):2022-2032.

PMID: 36724452 PMC: 10163311. DOI: 10.1182/blood.2022018083.

Factor IX(a) inhibitors: an updated patent review (2003-present).

Afosah D, Ofori E, Mottamal M, Al-Horani R Expert Opin Ther Pat. 2022; 32(4):381-400.

PMID: 34991418 PMC: 8957558. DOI: 10.1080/13543776.2022.2026926.

Murine Models in the Evaluation of Heparan Sulfate-Based Anticoagulants.

Mohammed B, Cheng Q, Ivanov I, Gailani D Methods Mol Biol. 2021; 2303:789-805.

PMID: 34626423 PMC: 8552346. DOI: 10.1007/978-1-0716-1398-6_59.

Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction.

Knight K, Coyle C, Radford C, Parker E, Fedanov A, Shields J Blood Adv. 2021; 5(17):3333-3343.

PMID: 34477814 PMC: 8525220. DOI: 10.1182/bloodadvances.2021004742.

References

Misenheimer T, Buyue Y, Sheehan J . The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X. Biochemistry. 2007; 46(26):7886-95. DOI: 10.1021/bi7004703. View

Lin H, Maeda N, SMITHIES O, Straight D, Stafford D . A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997; 90(10):3962-6. View

Fay P, Koshibu K, Mastri M . The A1 and A2 subunits of factor VIIIa synergistically stimulate factor IXa catalytic activity. J Biol Chem. 1999; 274(22):15401-6. DOI: 10.1074/jbc.274.22.15401. View

Wang X, Smith P, Hsu M, Gailani D, Schumacher W, Ogletree M . Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006; 4(9):1982-8. DOI: 10.1111/j.1538-7836.2006.02093.x. View

Yuan Q, Walke E, Sheehan J . The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry. 2005; 44(9):3615-25. DOI: 10.1021/bi047934a. View

Hron G, Kollars M, Binder B, Eichinger S, Kyrle P . Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006; 296(4):397-402. DOI: 10.1001/jama.296.4.397. View

Chang J, Jin J, Lollar P, Bode W, Brandstetter H, Hamaguchi N . Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998; 273(20):12089-94. DOI: 10.1074/jbc.273.20.12089. View

Hoffman M, Monroe D, Oliver J, Roberts H . Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood. 1995; 86(5):1794-801. View

Wang X, Cheng Q, Xu L, Feuerstein G, Hsu M, Smith P . Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005; 3(4):695-702. DOI: 10.1111/j.1538-7836.2005.01236.x. View

10.

Brummel-Ziedins K, Vossen C, Rosendaal F, Umezaki K, Mann K . The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost. 2005; 3(7):1472-81. PMC: 1414093. DOI: 10.1111/j.1538-7836.2005.01249.x. View

11.

Pittman D, Kaufman R . Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A. 1988; 85(8):2429-33. PMC: 280010. DOI: 10.1073/pnas.85.8.2429. View

12.

Lenting P, Donath M, van Mourik J, Mertens K . Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994; 269(10):7150-5. View

13.

Eaton D, Rodriguez H, Vehar G . Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986; 25(2):505-12. DOI: 10.1021/bi00350a035. View

14.

Lollar P, Knutson G, Fass D . Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid. Blood. 1984; 63(6):1303-8. View

15.

Gerotziafas G, Depasse F, Busson J, Leflem L, Elalamy I, Samama M . Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J. 2005; 3:16. PMC: 1291409. DOI: 10.1186/1477-9560-3-16. View

16.

Duffy E, Parker E, Mutucumarana V, Johnson A, Lollar P . Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem. 1992; 267(24):17006-11. View

17.

Fay P, Koshibu K . The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998; 273(30):19049-54. DOI: 10.1074/jbc.273.30.19049. View

18.

Jenkins P, Dill J, Zhou Q, Fay P . Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase. Biochemistry. 2004; 43(17):5094-101. DOI: 10.1021/bi036289p. View

19.

Hemker H, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R . Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15. DOI: 10.1159/000071636. View

20.

Shen B, Spiegel P, Chang C, Huh J, Lee J, Kim J . The tertiary structure and domain organization of coagulation factor VIII. Blood. 2007; 111(3):1240-7. PMC: 2214755. DOI: 10.1182/blood-2007-08-109918. View